Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 20/20 | 0.40 |
| ▸ | S1PR4 | O95977 | 2/20 | 0.35 |
| ▸ | S1PR5 | Q9H228 | 2/20 | 0.35 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14584258 | 0.84 | CYP11B1 (0.41) | S1PR1 | |
| SCHEMBL5522526 | 0.82 | PTGDR (0.38) | S1PR1 | |
| SCHEMBL5420470 | 0.79 | PTGDR (0.48) | S1PR1S1PR4S1PR5ADORA3 | |
| SCHEMBL4093843 | 0.79 | PTGDR (0.48) | S1PR1S1PR4S1PR5ADORA3 | |
| SCHEMBL5520082 | 0.76 | S1PR1 (0.48) | S1PR1S1PR4S1PR5ADORA3 | |
| SCHEMBL6820539 | 0.75 | TBXA2R (0.53) | S1PR1 | |
| SCHEMBL1255235 | 0.72 | PDE2A (0.50) | S1PR1 | |
| SCHEMBL27999226 | 0.72 | DGAT1 (0.38) | — | |
| SCHEMBL30762333 | 0.69 | SIRT1 (0.58) | S1PR1 | |
| SCHEMBL29141422 | 0.69 | SIRT1 (0.58) | S1PR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070027171-A1 | Cycloalkanepyrrolopyridines as dp receptor antagonists | MERCK FROSST CANADA LTD. (CA) | 2007-02-01 | — | — | US | disclosed |
| EP-1638967-A2 | CYCLOALKANEPYRROLOPYRIDINES AS DP RECEPTOR ANTAGONISTS | Merck Frosst Canada Ltd. (CA) | 2006-03-29 | — | — | EP | disclosed |
| WO-2004111047-A2 | CYCLOALKANEPYRROLOPYRIDINES AS DP RECEPTOR ANTAGONISTS | MERCK FROSST CANADA LTD. (CA) | 2004-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070027171-A1 | Cycloalkanepyrrolopyridines as dp receptor antagonists | PTGIR, PTGDR, PTGDR2 | S1PR1 69/4885S1PR4 82/4885S1PR5 63/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.